PROGNYX

Home/The Watchtower/Daraxonrasib

Drug file · From the Watchtower

Daraxonrasib: the briefings and the record

Every Prognyx briefing on daraxonrasib, newest first, and the dated events drawn from the sources those briefings cite. Rebuilt with each new briefing.

Also known as
RMC-6236, Rasonque
Target, as briefed
RAS G12D (RAS(ON) inhibitor); RAS (RAS(ON) multi-selective inhibitor)
Companies named
Revolution Medicines
Prognyx coverage
2 briefings, 24 July 2026 to 5 October 2026

Prognyx briefings on daraxonrasib

  1. first-line metastatic RAS G12D pancreatic cancerRevolution Medicines begins dosing its RAS(ON) doublet in G12D pancreatic cancer

    Revolution Medicines has begun treating patients in RASolute 309 (NCT07805954), a global Phase 3 study pitting its RAS(ON) doublet against gemcitabine and nab-paclitaxel in first-line metastatic RAS G12D pancreatic cancer, with primary completion targeted for March 2029.

  2. Pretreated metastatic pancreatic cancerDaraxonrasib's NDA is accepted with a National Priority Voucher, which puts an FDA decision in weeks, not mid-2027

    Revolution Medicines' 22 July release confirms the FDA accepted the daraxonrasib NDA in previously treated metastatic pancreatic cancer, and that the asset sits in the Commissioner's National Priority Voucher pilot, a programme the FDA targets at 1–2 months against 6+. No action date is published, but the voucher, not the acceptance, is the number a competitor should be planning against.

Sourced timeline

Readouts, regulatory actions, filings, trial starts and deals that the Prognyx engine extracted from the documents cited in these briefings, newest first. Each links to its source and to the briefing that cited it. Press coverage is left out, and so is any event dated on its own briefing's day: the briefing above is the record for that day. A month without a day is a date the source gave only to the month.

  1. Regulatory actionFDA approves RASONQUE for 2L metastatic PDACSEC 8-K (Revolution Medicines) · cited in Revolution Medicines begins dosing its RAS(ON) doublet in G12D…
  2. Trial startGlobal Phase 3 RASolute 309 initiatedSEC 8-K Exhibit 99.1 (Revolution Medicines Q2 2026 results) · cited in Revolution Medicines begins dosing its RAS(ON) doublet in G12D…
  3. ReadoutPreclinical study links CDK8 to daraxonrasib resistance in PDACThe EMBO Journal (peer-reviewed, published 2026-07-11) · cited in Daraxonrasib's NDA is accepted with a National Priority Voucher…
  4. ReadoutRASolute 302 meets all primary and key secondary endpointsSEC 8-K (Royalty Pharma plc, filed 2026-04-13) · cited in Daraxonrasib's NDA is accepted with a National Priority Voucher…
  5. DealPositive Phase 3 results trigger $250 million funding milestoneSEC 8-K (Royalty Pharma plc, filed 2026-04-13) · cited in Daraxonrasib's NDA is accepted with a National Priority Voucher…
  6. Readout300 mg subgroup shows 8.8-month median PFS in KRAS G12X PDACSEC 8-K (RVMD, filed 2025-02-26) · cited in Daraxonrasib's NDA is accepted with a National Priority Voucher…
  7. ReadoutMonotherapy safety datasets report no TRAE-driven discontinuationsSEC 8-K (RVMD, filed 2025-02-26) · cited in Daraxonrasib's NDA is accepted with a National Priority Voucher…
  8. ReadoutEarlier RAS-mutant PDAC data show 7.6-month PFS and 14.5-month OSSEC 8-K (RVMD, filed 2025-02-26) · cited in Daraxonrasib's NDA is accepted with a National Priority Voucher…

Registered trials on file

ClinicalTrials.gov records that the cited sources tie to daraxonrasib, each opening on the registry.

Want this on your pipeline?
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.

Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use. Event titles are written by the Prognyx engine from the linked source; the source is the record.